These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 24041597)

  • 21. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients.
    Pinto VM; Balocco M; Quintino S; Bacigalupo L; Gianesin B; Rizzi M; Malagò R; De Franceschi L; Forni GL
    Am J Hematol; 2018 Oct; 93(10):E338-E340. PubMed ID: 30033633
    [No Abstract]   [Full Text] [Related]  

  • 23. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective.
    Musallam KM; Cappellini MD; Wood JC; Taher AT
    Blood Rev; 2012 Apr; 26 Suppl 1():S16-9. PubMed ID: 22631036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment and treatment of cardiac iron overload in thalassemia.
    Aessopos A; Farmakis D; Andreopoulos A; Tsironi M
    Hemoglobin; 2009; 33 Suppl 1():S87-92. PubMed ID: 20001638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron chelation therapy for transfusional iron overload: a swift evolution.
    Musallam KM; Taher AT
    Hemoglobin; 2011; 35(5-6):565-73. PubMed ID: 21910602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of Transfusion and Iron Chelation in Thalassemias.
    Porter JB; Garbowski MW
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):247-259. PubMed ID: 29458730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron chelation therapy in myelodysplastic syndrome - Cui bono?
    Tefferi A; Stone RM
    Leukemia; 2009 Aug; 23(8):1373. PubMed ID: 19672273
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
    Peng CT; Tsai CH; Wu KH
    Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 31. The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):283-6. PubMed ID: 19814673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
    Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenesis and management of iron toxicity in thalassemia.
    Hershko C
    Ann N Y Acad Sci; 2010 Aug; 1202():1-9. PubMed ID: 20712765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron chelation therapy in MDS: does it improve survival?
    Leitch HA
    Leuk Res; 2010 Jul; 34(7):852-3. PubMed ID: 20346508
    [No Abstract]   [Full Text] [Related]  

  • 35. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
    Porter JB; Shah FT
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF; Peng CT; Wu KH; Tsai CH
    Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver iron overload assessment by T *2 magnetic resonance imaging in pediatric patients: an accuracy and reproducibility study.
    Cheng HL; Holowka S; Moineddin R; Odame I
    Am J Hematol; 2012 Apr; 87(4):435-7. PubMed ID: 22286974
    [No Abstract]   [Full Text] [Related]  

  • 39. [Post-transfusional iron overload, iron loading anemia].
    Rose C
    Rev Med Interne; 2012 Jun; 33 Suppl 1():S15-8. PubMed ID: 22475955
    [No Abstract]   [Full Text] [Related]  

  • 40. Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study.
    Messa E; Biale L; Castiglione A; Lunghi M; Bonferroni M; Salvi F; Allione B; Ferrero D; Calabrese C; De Gobbi M; Nicoli P; Gioia D; Levis A; Saglio G; Cilloni D
    Leuk Lymphoma; 2017 Nov; 58(11):2752-2754. PubMed ID: 28482720
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.